AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Glycivas M 30mg/500mg Tablet PR

Prescription Icon
Prescription Required

Marketer

Cresha Lifesciences

Salt Composition

Gliclazide (30mg) + Metformin (500mg)

Overview Glycivas M 30mg/500mg Tablet PR

Diabetic patients using the combination drug Glycivas M (30mg/500mg) tablets should adhere to prescribed dosages. This anti-diabetic medication, a dual-component formulation, manages type 2 diabetes in adults by regulating blood glucose. Always take this medication with food, consistently at the same time daily for optimal efficacy. Dosage adjustments are determined by your physician based on your blood sugar response. Continuous use is crucial; discontinuation without medical consultation risks elevated blood sugar, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. This medication complements a comprehensive diabetes management plan, including dietary modifications, exercise, and weight management as directed by your healthcare provider. Lifestyle choices significantly influence diabetes control. Common side effects include hypoglycemia (low blood sugar), characterized by symptoms like sweating, dizziness, headache, and tremors; promptly treat with a fast-acting glucose source. Constipation and vomiting are also possible. Prevent hypoglycemia with regular meals and readily available glucose. Alcohol consumption should be avoided due to its interaction with Glycivas M and increased hypoglycemia risk. Less frequent side effects may include altered taste perception, nausea, diarrhea, abdominal discomfort, and upper respiratory infections. Weight gain is a potential consequence. This medication is contraindicated for type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Individuals with a history of cardiovascular disease should inform their physician before commencing treatment. Pregnant or lactating women require medical consultation prior to use. Regular blood glucose monitoring and periodic blood tests to assess blood cell counts and liver function are recommended.

Primary Ingredients of Glycivas M 30mg/500mg Tablet PR

No text was provided to rewrite.

Uses of Glycivas M 30mg/500mg Tablet PR

Adult-onset diabetes

Major Benefits of Glycivas M 30mg/500mg Tablet PR:

Follow your physician's instructions or consult the product label for proper administration. Take Glycivas M 30mg/500mg Tablet PR with meals.

Common Side effects of Glycivas M 30mg/500mg Tablet PR:

  • Hypoglycemia (low blood glucose level)
  • Headache
  • Dizziness
  • Diarrhea
  • Upper respiratory tract infection
  • Nausea
  • Flatulence
  • Constipation

How to use Glycivas M 30mg/500mg Tablet PR:

Follow your physician's instructions or consult the product label for proper administration. Ingest Glycivas M 30mg/500mg Tablet PR with a meal.

How Glycivas M 30mg/500mg Tablet PR works:

Glycivas M 30mg/500mg tablets are a dual-action antidiabetic formulation containing gliclazide and metformin.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Glycivas M 30mg/500mg Tablet PR with alcohol is inadvisable due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

Using Glycivas M 30mg/500mg tablets during pregnancy poses a confirmed risk to the fetus. Therefore, it's not recommended. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential advantages outweigh the dangers. Always seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Breastfeeding while taking Glycivas M 30mg/500mg tablets is likely unsafe. Available human data indicates potential transfer of the medication into breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Impaired driving is possible with excessively low or high blood glucose levels. Refrain from driving if such symptoms arise.

KidneyKidneyCAUTION

Patients with kidney impairment should use Glycivas M 30mg/500mg Tablet PR cautiously, potentially requiring dosage modification. Physician consultation is essential. Glycivas M 30mg/500mg Tablet PR is contraindicated in individuals with severe kidney disease. Routine monitoring of kidney function is recommended during treatment.

LiverLiverCAUTION

Patients with liver impairment should use Glycivas M 30mg/500mg Tablet PR cautiously, potentially requiring dosage modification. Individuals with mild to moderate liver disease should begin with a low Glycivas M 30mg/500mg Tablet PR dose; however, its use is contraindicated in those with severe hepatic dysfunction. Medical advice is essential.

What if you forget to take Glycivas M 30mg/500mg Tablet PR :

Should you forget a Glycivas M 30mg/500mg Tablet PR dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Glycivas M 30mg/500mg Tablet PR

LabelValue
Developing Habits No.
Treatment Category Diabetes Treatment

FAQs on Glycivas M 30mg/500mg Tablet PR

Glycivas M 30mg/500mg tablets combine gliclazide and metformin to manage type 2 diabetes mellitus in adults. This combination improves blood sugar control when used with diet and exercise. Gliclazide boosts insulin release from the pancreas, while metformin reduces liver glucose production and enhances insulin sensitivity. It's not suitable for type 1 diabetes.
Glycivas M 30mg/500mg Tablet PR may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory tract infections. Rare but serious side effects, including lactic acidosis, are also possible. Prolonged use may result in vitamin B12 deficiency.
Glycivas M 30mg/500mg Tablet PR can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, or shakiness. This risk increases with missed meals, alcohol consumption, excessive exercise, or concurrent use of other diabetes medications. Regular blood sugar monitoring is crucial. Carry glucose tablets, honey, or fruit juice for emergencies.
Glycivas M 30mg/500mg Tablet PR can cause lactic acidosis (MALA—Metformin-associated lactic acidosis), a serious medical emergency resulting from excessive blood lactic acid. This rare side effect is best avoided in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, stop taking Glycivas M and seek immediate medical attention.
Prolonged Glycivas M 30mg/500mg Tablet PR use can lead to vitamin B12 deficiency by impairing its stomach absorption. This deficiency, if left untreated, may result in anemia, neurological issues such as tingling, numbness in extremities, weakness, urinary problems, cognitive changes, and ataxia. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Glycivas M 30mg/500mg Tablet PR is contraindicated in patients with allergies to its ingredients or excipients, and in those with moderate to severe kidney disease or metabolic acidosis (including diabetic ketoacidosis).
Combining Glycivas M 30mg/500mg tablets with alcohol is unsafe. This combination risks dangerously low blood sugar (hypoglycemia) and increased lactic acidosis.
Glycivas M 30mg/500mg tablets combine gliclazide and metformin to manage type 2 diabetes mellitus in adults. This medication improves blood sugar control when used with a healthy diet and exercise. Gliclazide stimulates insulin release from the pancreas, while metformin reduces liver glucose production and enhances insulin sensitivity. It's not suitable for type 1 diabetes.
Glycivas M 30mg/500mg Tablet PR may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects, including lactic acidosis, are also possible. Prolonged use may result in vitamin B12 deficiency.
Glycivas M 30mg/500mg Tablet PR can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heart rate, anxiety, or shakiness. This risk increases with missed meals, alcohol consumption, excessive exercise, or concurrent use of other diabetes medications. Regular blood sugar monitoring is crucial. Carry glucose tablets, honey, or fruit juice for emergencies.
Glycivas M 30mg/500mg Tablet PR can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This rare side effect is more likely in patients with kidney disease, older adults, or those who consume large amounts of alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Glycivas M 30mg/500mg Tablet PR and seek immediate medical attention.
Prolonged Glycivas M 30mg/500mg Tablet PR use can lead to vitamin B12 deficiency by hindering its stomach absorption. This deficiency, if left unaddressed, may result in anemia, neurological issues such as tingling, numbness in extremities, weakness, urinary problems, cognitive changes, and ataxia. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Glycivas M 30mg/500mg Tablet PR is contraindicated in patients with allergies to its components or excipients, and in those with moderate-to-severe kidney disease or metabolic acidosis (including diabetic ketoacidosis).
Combining Glycivas M 30mg/500mg tablets with alcohol is unsafe. This combination can dangerously lower blood sugar (causing hypoglycemia) and raise the risk of lactic acidosis.
Glycivas M 30mg/500mg Tab...
53
MRP 65
18% off